What is the clinical evidence from this study?

Study design: Other. Population: Type 2 diabetic cardiomyopathy (n=60). Intervention: AZD1656 vs. Untreated db/db mice. Primary outcome: Cardiac oxygen consumption.

What does this research mean for the field?

AZD1656 improves myocardial performance and reduces cardiac dysfunction in type 2 diabetic cardiomyopathy by targeting immunometabolic pathways. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The research aims to explore the therapeutic potential of AZD1656 in alleviating heart problems caused by type 2 diabetes.

February 25, 2026Nature Cardiovascular Research1 citationsOpen Access

Targeting immunometabolic pathways with AZD1656 alleviates inflammation and metabolic dysfunction in type 2 diabetic cardiomyopathy

SAStephanie A. AndersonUniversity of Oxford AKAnja KarlstaedtCardio-Oncology MYMegan YoungQueen Mary University of London

Key Result

AZD1656 treatment reduced cardiac oxygen consumption by 68% and attenuated diastolic dysfunction and infarct size in mice with type 2 diabetic cardiomyopathy.

Key Points

The research aims to explore the therapeutic potential of AZD1656 in alleviating heart problems caused by type 2 diabetes.
Administered AZD1656 to obese, hyperglycemic db/db mice for 6 weeks.
Conducted analyses of myocardial performance, infarct size, and post-ischaemic recovery.
Performed integrated assessments of metabolic and histological changes in cardiac tissue.
AZD1656 treatment improved myocardial performance and reduced heart damage.
Enhanced heart recovery after ischemia was observed.
Restoration of mitochondrial function and decreased fibrosis were noted.

Structured PICO

Does the glucokinase activator AZD1656 improve cardiac function and metabolic remodeling in a mouse model of type 2 diabetic cardiomyopathy?

Population

Obese, hyperglycemic db/db mice (BKS.Cg- Dock7m+/+ Leprdb/J) with diastolic dysfunction (model of type 2 diabetic cardiomyopathy) and lean controls (het Dock7m+/+ Leprdb).

Intervention

AZD1656 (glucokinase activator) 30 mg/kg body weight added to diet for 6 weeks.

Comparator

Untreated db/db mice fed nutritionally standardized and matched standard base diet.

Outcome

Cardiac diastolic function (isovolumic relaxation time, mitral valve deceleration, myocardial performance index, E/A ratio), infarct size after ischemia-reperfusion injury, and cardiac metabolic flux.surrogate

AZD1656 improves cardiac diastolic function, reduces infarct size, and restores metabolic flexibility in diabetic cardiomyopathy by modulating the cardiac immune landscape, independent of systemic glycemic control.

Abstract

Abstract Type 2 diabetes (T2D) precipitates diabetic cardiomyopathy (dbCM), a condition characterized by chronic inflammation, metabolic dysregulation and impaired cardiac performance. Here we show that the glucokinase activator AZD1656, originally developed for glycemic control but later identified to have immunomodulatory effects, reverses cardiac dysfunction and metabolic remodeling in dbCM. In obese, hyperglycemic db/db mice with diastolic dysfunction, 6 weeks of AZD1656 treatment improved myocardial performance, reduced infarct size and enhanced post-ischaemic recovery. Integrated metabolic, functional and histological analyses revealed restoration of mitochondrial metabolism and attenuation of fibrosis. Mechanistically, AZD1656 remodeled the cardiac immune landscape by promoting infiltration of regulatory T cells. These findings demonstrate a link between cardiac inflammation and metabolic remodeling in dbCM and highlight that modulation of immune cells and metabolism can protect the diabetic heart. Targeting immunometabolic pathways may therefore offer a therapeutic strategy to alleviate cardiac dysfunction and reduce infarct vulnerability in T2D.

问 AI

Bookmark

View Full Paper